Abstract
Motivation Cancer is a collection of diseases caused by the deregulation of cell processes, which is triggered by somatic mutations. The search for patterns in somatic mutations, known as mutational signatures, is a growing field of study that has already became a useful tool in oncology. Several algorithms have been proposed to perform one or both the following two tasks: 1) de novo estimation of signatures and their exposures, 2) estimation of the exposures of each one of a set of pre-defined signatures. Our group developed signeR, a Bayesian approach to both these tasks.
Results Here we present a new version of the software, signeR 2.0, which extends the possibilities of previous analyses to explore the relation of signature exposures to other data of clinical relevance. signeR 2.0 includes an user-friendly interface developed using the R-Shiny framework and improvements in performance. This version allows the analysis of submitted data or public TCGA data, which is embedded on the package for easy access.
Availability signer 2.0 is an open-source R package available through the Bioconductor project at https://doi.org/doi:10.18129/B9.bioc.signeR
Contact itojal{at}accamargo.org.br or rrosales{at}usp.br
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was partially supported by Fundacao de Apoio a Pesquisa do Estado de Sao Paulo (FAPESP), grant 2022/12991-0. ED-N is a research fellow from Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, Brazil (CNPq) and acknowledges the support received from Associacao Beneficente Alzira Denise Hertzog Silva (ABADHS) and FAPESP grant 14/26897-0.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
https://portal.gdc.cancer.gov/
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Funding: This work was partially supported by Fundação de Apoio a Pesquisa do Estado de São Paulo (FAPESP), grant 2022/12991-0. ED-N is a research fellow from Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, Brazil (CNPq) and acknowledges the support received from Associação Beneficente Alzira Denise Hertzog Silva (ABADHS) and FAPESP grant 14/26897-0.
Competing interests: The author declare no competing interests.
Data Availability
All data produced are available online at https://doi.org/doi:10.18129/B9.bioc.signeR
